1. Home
  2. PAYS vs ALT Comparison

PAYS vs ALT Comparison

Compare PAYS & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAYS
  • ALT
  • Stock Information
  • Founded
  • PAYS 2001
  • ALT 1997
  • Country
  • PAYS United States
  • ALT United States
  • Employees
  • PAYS N/A
  • ALT N/A
  • Industry
  • PAYS Business Services
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • PAYS Consumer Discretionary
  • ALT Health Care
  • Exchange
  • PAYS Nasdaq
  • ALT Nasdaq
  • Market Cap
  • PAYS 303.3M
  • ALT 348.6M
  • IPO Year
  • PAYS 1998
  • ALT N/A
  • Fundamental
  • Price
  • PAYS $5.44
  • ALT $4.00
  • Analyst Decision
  • PAYS Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • PAYS 4
  • ALT 7
  • Target Price
  • PAYS $8.06
  • ALT $16.50
  • AVG Volume (30 Days)
  • PAYS 484.1K
  • ALT 2.7M
  • Earning Date
  • PAYS 11-12-2025
  • ALT 11-07-2025
  • Dividend Yield
  • PAYS N/A
  • ALT N/A
  • EPS Growth
  • PAYS N/A
  • ALT N/A
  • EPS
  • PAYS 0.12
  • ALT N/A
  • Revenue
  • PAYS $68,539,381.00
  • ALT $20,000.00
  • Revenue This Year
  • PAYS $35.44
  • ALT N/A
  • Revenue Next Year
  • PAYS $21.93
  • ALT N/A
  • P/E Ratio
  • PAYS $47.84
  • ALT N/A
  • Revenue Growth
  • PAYS 27.84
  • ALT N/A
  • 52 Week Low
  • PAYS $1.80
  • ALT $2.90
  • 52 Week High
  • PAYS $8.88
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • PAYS 50.32
  • ALT 54.65
  • Support Level
  • PAYS $5.39
  • ALT $3.83
  • Resistance Level
  • PAYS $6.10
  • ALT $4.15
  • Average True Range (ATR)
  • PAYS 0.23
  • ALT 0.16
  • MACD
  • PAYS 0.02
  • ALT 0.01
  • Stochastic Oscillator
  • PAYS 54.43
  • ALT 70.30

About PAYS Paysign Inc.

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: